REPORT ID 513

EMEA (Europe, Middle East and Africa) Acute Respiratory Distress Syndrome Therapeutics Market Report 2017

Publish Date
04-Dec-17
Pages
106
Format
Electronic (PDF)

In this report, the EMEA Acute Respiratory Distress Syndrome Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Acute Respiratory Distress Syndrome Therapeutics for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Acute Respiratory Distress Syndrome Therapeutics market competition by top manufacturers/players, with Acute Respiratory Distress Syndrome Therapeutics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Therabron Therapeutics, Inc.
    Serendex Pharmaceuticals A/S
    Silence Therapeutics Plc
    Histocell S.L.
    Altor BioScience Corporation
    Athersys, Inc.
    Faron Pharmaceuticals Oy
    FirstString Research, Inc.
    GlaxoSmithKline Plc
    Phylogica Limited

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Methylprednisolone
    Hydrocortisone
    Calf Pulmonary Surfactant for Injection
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    In-Patient
    Out-Patient

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Acute Respiratory Distress Syndrome Therapeutics Market Report 2017
1 Acute Respiratory Distress Syndrome Therapeutics Overview
    1.1 Product Overview and Scope of Acute Respiratory Distress Syndrome Therapeutics
    1.2 Classification of Acute Respiratory Distress Syndrome Therapeutics
        1.2.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Methylprednisolone
        1.2.4 Hydrocortisone
        1.2.5 Calf Pulmonary Surfactant for Injection
        1.2.6 Others
    1.3 EMEA Acute Respiratory Distress Syndrome Therapeutics Market by Application/End Users
        1.3.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 In-Patient
        1.3.3 Out-Patient
    1.4 EMEA Acute Respiratory Distress Syndrome Therapeutics Market by Region
        1.4.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Acute Respiratory Distress Syndrome Therapeutics (2012-2022)
        1.5.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2012-2022)

2 EMEA Acute Respiratory Distress Syndrome Therapeutics Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Market Competition by Players/Manufacturers
        2.1.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Acute Respiratory Distress Syndrome Therapeutics Sale Price by Players (2012-2017)
    2.2 EMEA Acute Respiratory Distress Syndrome Therapeutics (Volume and Value) by Type/Product Category
        2.2.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Acute Respiratory Distress Syndrome Therapeutics Sale Price by Type (2012-2017)
    2.3 EMEA Acute Respiratory Distress Syndrome Therapeutics (Volume) by Application
    2.4 EMEA Acute Respiratory Distress Syndrome Therapeutics (Volume and Value) by Region
        2.4.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales Price by Region (2012-2017)

3 Europe Acute Respiratory Distress Syndrome Therapeutics (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Acute Respiratory Distress Syndrome Therapeutics Sales and Value (2012-2017)
        3.1.1 Europe Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2012-2017)
    3.2 Europe Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Type
    3.3 Europe Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Application
    3.4 Europe Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Acute Respiratory Distress Syndrome Therapeutics Sales Volume by Countries (2012-2017)
        3.4.2 Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries (2012-2017)
        3.4.3 Germany Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        3.4.4 France Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        3.4.5 UK Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        3.4.6 Russia Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        3.4.7 Italy Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)

4 Middle East Acute Respiratory Distress Syndrome Therapeutics (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Acute Respiratory Distress Syndrome Therapeutics Sales and Value (2012-2017)
        4.1.1 Middle East Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2012-2017)
    4.2 Middle East Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Type
    4.3 Middle East Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Application
    4.4 Middle East Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Acute Respiratory Distress Syndrome Therapeutics Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        4.4.4 Israel Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        4.4.5 UAE Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        4.4.6 Iran Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)

5 Africa Acute Respiratory Distress Syndrome Therapeutics (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Acute Respiratory Distress Syndrome Therapeutics Sales and Value (2012-2017)
        5.1.1 Africa Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2012-2017)
    5.2 Africa Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Type
    5.3 Africa Acute Respiratory Distress Syndrome Therapeutics Sales and Market Share by Application
    5.4 Africa Acute Respiratory Distress Syndrome Therapeutics Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Acute Respiratory Distress Syndrome Therapeutics Sales Volume by Countries (2012-2017)
        5.4.2 Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries (2012-2017)
        5.4.3 South Africa Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate (2012-2017)

6 EMEA Acute Respiratory Distress Syndrome Therapeutics Manufacturers/Players Profiles and Sales Data
    6.1 Therabron Therapeutics, Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Serendex Pharmaceuticals A/S
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Silence Therapeutics Plc
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Histocell S.L.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Altor BioScience Corporation
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Athersys, Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Faron Pharmaceuticals Oy
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 FirstString Research, Inc.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 GlaxoSmithKline Plc
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Phylogica Limited
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Acute Respiratory Distress Syndrome Therapeutics Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Acute Respiratory Distress Syndrome Therapeutics Manufacturing Cost Analysis
    7.1 Acute Respiratory Distress Syndrome Therapeutics Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Acute Respiratory Distress Syndrome Therapeutics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Acute Respiratory Distress Syndrome Therapeutics Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Acute Respiratory Distress Syndrome Therapeutics Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2017-2022)
    11.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Acute Respiratory Distress Syndrome Therapeutics Price and Trend Forecast (2017-2022)
    11.2 EMEA Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Growth Rate Forecast by Regi